OncoCyte (OCX) Earnings Date, Estimates & Call Transcripts $3.44 +0.05 (+1.33%) As of 12:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OncoCyte Earnings Summary Upcoming Earnings DateMay. 13After Market ClosesEstimatedConsensus EPS (Mar. 24) -$0.40 Actual EPS (Mar. 24) $0.48 Beat By $0.88 Actual Revenue (Mar. 24) $1.49MOncoCyte issued Q4 2024 earnings on March 24, 2025, reporting an EPS of $0.48, which topped analysts' consensus estimates of -$0.40 by $0.88. Quarterly revenue was reported to be $1.49 million, above analyst estimates of $0.16 million. With a trailing EPS of -$4.40, OncoCyte's earnings are expected to grow next year, from ($2.57) to ($1.40) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Annual Report (10-K)OCX Upcoming EarningsOncoCyte's next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules. Powered by Get OncoCyte Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OncoCyte and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataOCX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.OCX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. OncoCyte Analyst EPS EstimatesCurrent Year EPS Consensus Estimate ($2.57) EPSNext Year EPS Consensus Estimate ($1.40) EPS OncoCyte Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/13/2025(Estimated)--------3/24/2025Q4 2024-$0.40$0.48+$0.88-$1.93$0.16M$1.49M11/12/2024Q3 2024-$0.44-$0.98 -$0.54-$0.98-$0.12M8/8/2024Q2 2024--$0.36 -$0.36-$0.36-$0.10M5/15/2024Q1 2024--$1.13 -$1.13-$1.13-$0.18M11/9/2023Q3 2023-$1.52-$0.57+$0.95-$0.33$0.40M$0.43M8/10/2023Q2 2023-$2.60-$1.07+$1.53-$1.07$0.60M$0.46M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$2.00$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$2.00$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$2.00$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M Get the Latest News and Ratings for OCX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30MNew “Trump” currency proposed in DC (Ad)According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. When you see what could happen – I think you’ll be excited.5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M5/11/2023Q1 2023-$2.40-$0.80+$1.60-$0.10$0.50M$0.30M OncoCyte Earnings - Frequently Asked Questions When is OncoCyte's earnings date? OncoCyte has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based off last year's report dates. Learn more on OCX's earnings history. Did OncoCyte beat their earnings estimates last quarter? In the previous quarter, OncoCyte (NASDAQ:OCX) reported $0.48 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.40) by $0.88. Learn more on analysts' earnings estimate vs. OCX's actual earnings. How can I listen to OncoCyte's earnings conference call? The conference call for OncoCyte's latest earnings report can be listened to online. Listen to Conference Call How can I read OncoCyte's conference call transcript? The conference call transcript for OncoCyte's latest earnings report can be read online. Read Transcript How much revenue does OncoCyte generate each year? OncoCyte (NASDAQ:OCX) has a recorded annual revenue of $1.88 million. How much profit does OncoCyte generate each year? OncoCyte (NASDAQ:OCX) has a recorded net income of -$27.78 million. OCX has generated -$4.40 earnings per share over the last four quarters. What is OncoCyte's EPS forecast for next year? OncoCyte's earnings are expected to grow from ($2.57) per share to ($1.40) per share in the next year. More Earnings Resources from MarketBeat Related Companies OLMA Earnings BNTC Earnings CMPS Earnings TKNO Earnings ALLO Earnings TRDA Earnings ARCT Earnings TSHA Earnings HRTX Earnings ATYR Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step In This page (NASDAQ:OCX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCX Stock Free OCX Stock Alerts